Previous investigations have demonstrated an upregulation of Trophoblast cell surface antigen‐2 (Trop‐2) across various human solid tumors, including both primary and metastasized prostate cancer, which is associated with an increased risk of disease progression and unfavorable clinical outcomes.7 Here, TACSTD2 is linked to prostate cancer.